Although MAGE-A3 is one of the most immunogenic cancer-testis antigens, MAGE-A3 immunotherapeutics (recombinant MAGE-A3 associated with the adjuvant AS15) tested in 2 phase III clinical trials in melanoma and non-small cell carcinoma failed to improve disease-free survival, leading to discontinuation of this treatment development.49, 50. Here, MAGEA3 is linked to non-small cell lung carcinoma.